Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06994767 · ClinicalTrials.gov registry record · NA

Speech-derived Digital Biomarkers Study

A NA study, sponsored by Hackensack Meridian Health.

Completed
Registry status
NA
Development phase
150
Enrollment target

NCT06994767: Completed NA study, sponsored by Hackensack Meridian Health.

NCT06994767 is a NA study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 150 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06994767, a NA study, has completed, sponsored by Hackensack Meridian Health.

COMPLETED
Registry status
NA
Development phase
150 participants
Enrollment target

Study Summary

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

Primary Outcome

The CANARY application will use clinically validated survey instruments and voice recordings to analyze the data and determine the patient's MCI/ Alzheimer's disease diagnosis. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity, the application diagnosis will be compared against the clinical diagnosis of the physician.

Interventions

  • OTHER The Canary Application

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-05-19
Est. Completion 2026-01-09
Phase NA
Hackensack Meridian Health

90 total trials

What the finished NCT06994767 record still lists

NCT06994767 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).

The record links to 0 conditions, and to 1 intervention - of which The Canary Application is the first listed.

NCT06994767 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06994767 about?

NCT06994767 is a clinical study titled "Speech-derived Digital Biomarkers Study". The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

What is the current status of trial NCT06994767?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2025-05-19. Estimated completion is 2026-01-09.

What interventions are being tested in trial NCT06994767?

The interventions under investigation include: The Canary Application (OTHER).

Who is sponsoring clinical trial NCT06994767?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06994767's enrollment target sits among peer trials

150 661st of 2000 higher than 1,299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06994767, the US trial registry maintained by the National Library of Medicine. NCT06994767 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.